Shenzhen Chipscreen Biosciences Co., Ltd. (SHA:688321)
China · Delayed Price · Currency is CNY 30.19
-0.71 (-2.30%)
Mar 19, 2026, 3:00 PM CST
SHA:688321 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 909.54 | 644.5 | 517.57 | 526.43 | 430.19 |
Other Revenue | - | 13.45 | 6.14 | 3.51 | 0.26 |
| 909.54 | 657.95 | 523.71 | 529.94 | 430.45 | |
Revenue Growth (YoY) | 38.24% | 25.63% | -1.18% | 23.11% | 59.74% |
Cost of Revenue | - | 87.47 | 56.97 | 29.99 | 21.58 |
Gross Profit | 909.54 | 570.48 | 466.74 | 499.95 | 408.87 |
Selling, General & Admin | - | 408.13 | 364.33 | 316.78 | 288.82 |
Research & Development | - | 213.52 | 270.45 | 163.67 | 130.03 |
Other Operating Expenses | 858.63 | 12.12 | 11.5 | 13.12 | 3.01 |
Operating Expenses | 858.63 | 631.08 | 650.61 | 494.12 | 421.91 |
Operating Income | 50.9 | -60.6 | -183.87 | 5.82 | -13.04 |
Interest Expense | - | -34.25 | -34.88 | -20.13 | -4.72 |
Interest & Investment Income | - | 18.15 | 297.96 | 10.45 | 13.27 |
Currency Exchange Gain (Loss) | - | 1.93 | 2.22 | 8.43 | -1.62 |
Other Non Operating Income (Expenses) | -0.06 | -0.12 | -0.15 | -0.13 | -0.15 |
EBT Excluding Unusual Items | 50.84 | -74.88 | 81.29 | 4.45 | -6.25 |
Gain (Loss) on Sale of Investments | - | -21.6 | 0.84 | 0.82 | 0.08 |
Gain (Loss) on Sale of Assets | - | -0.05 | -0.03 | -0.71 | -0.13 |
Asset Writedown | - | -90.07 | - | - | - |
Other Unusual Items | - | 89.89 | 14.93 | 10.6 | 24.9 |
Pretax Income | 50.84 | -96.71 | 97.02 | 15.16 | 18.6 |
Income Tax Expense | -0.23 | 17.86 | 47.83 | 2.34 | -3.36 |
Earnings From Continuing Operations | 51.08 | -114.57 | 49.19 | 12.82 | 21.96 |
Minority Interest in Earnings | - | - | 39.65 | 4.67 | - |
Net Income | 51.08 | -114.57 | 88.84 | 17.48 | 21.96 |
Net Income to Common | 51.08 | -114.57 | 88.84 | 17.48 | 21.96 |
Net Income Growth | - | - | 408.09% | -20.37% | -29.27% |
Shares Outstanding (Basic) | 408 | 408 | 408 | 407 | 409 |
Shares Outstanding (Diluted) | 408 | 408 | 408 | 407 | 410 |
Shares Change (YoY) | -0.01% | -0.06% | 0.40% | -0.75% | -0.10% |
EPS (Basic) | 0.13 | -0.28 | 0.22 | 0.04 | 0.05 |
EPS (Diluted) | 0.13 | -0.28 | 0.22 | 0.04 | 0.05 |
EPS Growth | - | - | 406.05% | -19.78% | -29.20% |
Free Cash Flow | - | -192.36 | -386.3 | -356.87 | -163.68 |
Free Cash Flow Per Share | - | -0.47 | -0.95 | -0.88 | -0.40 |
Gross Margin | 100.00% | 86.71% | 89.12% | 94.34% | 94.99% |
Operating Margin | 5.60% | -9.21% | -35.11% | 1.10% | -3.03% |
Profit Margin | 5.62% | -17.41% | 16.96% | 3.30% | 5.10% |
Free Cash Flow Margin | - | -29.24% | -73.76% | -67.34% | -38.03% |
EBITDA | 107.55 | -3.95 | -141.84 | 42.75 | 0.59 |
EBITDA Margin | 11.82% | -0.60% | -27.08% | 8.07% | 0.14% |
D&A For EBITDA | 56.65 | 56.65 | 42.03 | 36.93 | 13.63 |
EBIT | 50.9 | -60.6 | -183.87 | 5.82 | -13.04 |
EBIT Margin | 5.60% | -9.21% | -35.11% | 1.10% | -3.03% |
Effective Tax Rate | - | - | 49.30% | 15.44% | - |
Revenue as Reported | - | 657.95 | 523.71 | 529.94 | 430.45 |
Advertising Expenses | - | 1.85 | 1.97 | 1.53 | 1.89 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.